Is Your Peptide Store Website FDA-Aligned? What 50+ Warning Letters Tell Us

The FDA didn’t send a memo before shutting down Amino Asylum in June 2025. Agents raided the warehouse, the site went offline the same day, and operations ceased immediately. One of the largest research peptide companies in the US — gone overnight.

That same year, the DOJ forced Tailor Made Compounding to forfeit $1.79 million for distributing unapproved peptides. And in a single day — September 9, 2025 — the FDA issued over 50 warning letters to peptide companies across the country.

Most of those businesses thought they were protected. They had “Research Use Only” disclaimers. They had legal counsel. They had been operating for years without incident. None of that mattered once FDA enforcement attention landed on their websites.

This article breaks down exactly what the FDA targets on peptide store websites, what claim patterns appear repeatedly in warning letters, and what you can check on your own site right now — before regulators do it for you.

Why Your Website Is the Highest-Risk Asset You Own

Most peptide store owners think about compliance in terms of products — which peptides are banned, which are in a gray zone, which compounding pharmacies are still operating. That framing misses the actual enforcement trigger.

The FDA’s primary tool against peptide sellers isn’t product seizure. It’s website content. Warning letters in 2024 and 2025 consistently cited specific language on product pages, homepages, blog posts, and social media. The products themselves were often secondary to the marketing claims surrounding them.

This matters because your payment processor reaches the same conclusion before the FDA does. High-risk merchant processors — the ones specifically built to serve this industry — monitor merchant websites for claim patterns flagged by Visa, Mastercard, and card network guidelines. When FDA enforcement pressure spikes in a category, processors audit their own portfolios. Merchants with flagged content get dropped. No warning. No appeal. No recourse.

The website is where your payment processing, your ad account, and your legal exposure all intersect. It’s the highest-risk asset you own — and most store owners haven’t reviewed it against current enforcement patterns.

What FDA Warning Letters Actually Flag

Reviewing warning letters issued to peptide sellers in 2024 and 2025 reveals consistent patterns. These are the claim types that appear most frequently.

1. Human efficacy claims disguised as research descriptions

The most common trigger. This includes language like “supports muscle recovery and tissue repair,” “promotes fat loss and improved body composition,” “enhances cellular regeneration,” or “known for its libido-enhancing effects.”

The “Research Use Only” disclaimer does not neutralize these claims. The FDA has explicitly stated in multiple warning letters that RUO language is not a legal shield when the surrounding content implies human use. If your product description reads like a supplement label, the disclaimer at the bottom changes nothing.

2. Selling banned substances

FDA removed BPC-157, Thymosin Beta-4 fragment, Melanotan II, and several other compounds from the list of permissible compounding substances in 2023. Stores still listing these products — even with heavy disclaimers — are operating in active enforcement territory.

Melanotan II carries additional risk because FDA issued a specific safety communication warning consumers against it. Describing it as “safe” for any purpose directly contradicts FDA’s public position.

3. Misleading FDA-approved framing

Tesamorelin is FDA-approved — but only for HIV-associated lipodystrophy. Using “FDA-approved” language to market it for general fat loss or body composition is a direct misrepresentation that appears in multiple recent warning letters. This extends to any language implying regulatory approval that doesn’t exist in the specific context being sold.

4. Anti-aging and disease-adjacent claims

Terms like “reverse aging,” “longevity,” “cellular repair,” and “immune support” exist in a claim category that both FDA and FTC monitor closely. FTC enforcement actions have specifically targeted health and wellness companies using these terms without substantiation.

5. Specific outcome timelines

Product pages stating “noticeable results within 4-6 weeks” or “improved energy within 2-3 weeks” are efficacy claims. They imply predictable human outcomes from a substance that has no approved clinical indication. This language pattern appears repeatedly in sites that received warning letters.

The “Research Use Only” Disclaimer Is Not Enough

This deserves its own section because it’s the most common misunderstanding in this industry. The FDA’s position, stated explicitly in warning letters, is that RUO disclaimers are “a ruse to avoid FDA scrutiny.”

If a product is being marketed in a way that implies human use — through claim language, testimonials, dosing guidance, or the product category itself — the disclaimer is legally irrelevant. Summit Research Peptides received an FDA warning letter in December 2024 despite marketing their products explicitly for the “scientific community” and “research applications.” The surrounding content on their product pages made the intended use clear enough that the disclaimer provided no protection.

Your disclaimer needs to be consistent with everything else on your site. If the product page reads like a health supplement listing and the disclaimer reads “not for human consumption,” FDA reads the product page — not the disclaimer.

A Practical Website Audit: What to Check Right Now

You don’t need a compliance consultant to do a first pass on your site. Here’s a structured review you can run yourself in under two hours.

Homepage and category pages

Read your homepage headline and subheadline as if you’ve never heard of peptides. Does it sound like a health product? Does it reference benefits to the human body? Does it position your store as a wellness destination? Red flags include any language about “your health,” “your body,” “feel better,” “recover faster,” or similar human outcome framing.

Product pages

For each product, check whether the description makes claims about human effects, whether any outcome language is tied to a timeframe, whether there are testimonials or before/after references, whether the product is on FDA’s banned substances list, and whether “FDA-approved” appears anywhere — and if so, whether it’s accurate for the specific indicated use.

Blog posts

Blog content carries the same regulatory weight as product pages. A blog post describing how to dose BPC-157 for injury recovery is an efficacy claim. Review your 10 most visited blog posts specifically for claim language — blog content is often less carefully written than product descriptions and frequently contains higher-risk language.

Disclaimer consistency

Your RUO disclaimer should appear on every product page, every blog post referencing specific compounds, and throughout the checkout flow. If it disappears at any stage, that inconsistency becomes a compliance gap.

The Enforcement Environment Is Getting Harsher, Not Easier

RFK Jr. has publicly stated he wants to loosen FDA restrictions on peptides. That has created a dangerous assumption in the industry that enforcement pressure is about to ease. The enforcement data tells a different story.

As of early 2026, no FDA rule has changed. No Federal Register notice has been published. No statute has been amended. Criminal indictments, raids, and warning letters continued through Q1 2026 at the same rate as 2025. Peptide Sciences — one of the most established vendors in the US — voluntarily shut down and pulled its entire catalog in March 2026.

RFK Jr.’s comments are policy direction. They are not law. Operating on the assumption that regulatory relief is coming before it actually arrives is not a legal defense.

What a Professional Website Audit Covers

A systematic audit goes beyond reading your own product pages. It cross-references your site content against current FDA warning letters and the specific claim patterns that triggered them, FTC enforcement actions on health and efficacy claims, the FDA’s current banned and restricted substances list, and card network content guidelines that high-risk processors are required to enforce.

Each finding is rated by severity — Red for immediate enforcement risk, Yellow for significant gray zone exposure, Green for lower priority — with specific fix recommendations for each issue.

Get a professional audit of your peptide store → PeptideFDAAudit.com

Reports are delivered within 2 business days. One-time, no subscription.

The Bottom Line

The FDA’s enforcement posture in the peptide space is the most aggressive it has been since 2023. Warning letters, raids, and criminal referrals are accelerating — not slowing down. The businesses getting hit aren’t rogue operations. They’re stores that look a lot like yours, selling similar products, with similar disclaimer language.

The difference between a warning letter and no warning letter often comes down to specific phrases on specific pages. That’s auditable. That’s fixable. But only if you know where to look.